Alicia C. Olivo - 14 Jan 2025 Form 4 Insider Report for NEOGENOMICS INC (NEO)

Role
EVP, GC & Business Development
Signature
/s/ Alicia C. Olivo
Issuer symbol
NEO
Transactions as of
14 Jan 2025
Net transactions value
$0
Form type
4
Filing time
16 Jan 2025, 16:11:08 UTC
Previous filing
19 Nov 2024
Next filing
25 Feb 2025
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
holding NEO Common Stock 39,414 14 Jan 2025 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction NEO Restricted Stock Unit Award $0 +59,382 $0.000000 59,382 14 Jan 2025 Common Stock 59,382 $0.000000 Direct F2
holding NEO Stock Option (Right to Buy) 1,046 14 Jan 2025 Common Stock 1,046 $19.12 Direct F3
holding NEO Stock Option (Right to Buy) 1,024 14 Jan 2025 Common Stock 1,024 $27.34 Direct F4
holding NEO Stock Option (Right to Buy) 516 14 Jan 2025 Common Stock 516 $48.99 Direct F5
holding NEO Stock Option (Right to Buy) 1,117 14 Jan 2025 Common Stock 1,117 $46.10 Direct F6
holding NEO Stock Option (Right to Buy) 22,222 14 Jan 2025 Common Stock 22,222 $9.45 Direct F7
holding NEO Stock Option (Right to Buy) 55,332 14 Jan 2025 Common Stock 55,332 $10.05 Direct F8
holding NEO Stock Option (Right to Buy) 36,508 14 Jan 2025 Common Stock 36,508 $19.65 Direct F9
holding NEO Performance Stock Unit 19,508 14 Jan 2025 Common Stock 19,508 $0.000000 Direct F2, F10
holding NEO Restricted Stock Unit 13,006 14 Jan 2025 Common Stock 13,006 $0.000000 Direct F2, F11
holding NEO Stock Option (Right to Buy) 42,344 14 Jan 2025 Common Stock 42,344 $16.45 Direct F12
holding NEO Performance Stock Unit 25,330 14 Jan 2025 Common Stock 25,330 $0.000000 Direct F2, F13
holding NEO Restricted Stock Unit 25,329 14 Jan 2025 Common Stock 25,329 $0.000000 Direct F2, F14
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 This balance includes 503 shares that were acquired pursuant to NeoGenomics' Employee Stock Purchase Plan ("ESPP"). The shares were acquired in transactions exempt from Section 16b-3. A Form 4 filed on August 5, 2024 included a footnote with reference to 378 ESPP shares having been acquired and a Form 4 filed on August 19, 2024 included a footnote with reference to 125 ESPP shares having been acquired, however those shares were inadvertently not reflected in the balance in Column 5 on those Form 4s. Those shares are now reflected in this balance.
F2 Once vested, the shares of common stock are not subject to expiration.
F3 On September 30, 2019, Ms. Olivo was granted 1,394 stock options. The options vested ratably over the first four anniversary dates of the grant date.
F4 On May 1, 2020, Ms. Olivo was granted 1,024 stock options. The options vest ratably over the first four anniversary dates of the grant date.
F5 On May 1, 2021, Ms. Olivo was granted 516 stock options. The options vest ratably over the first four anniversary dates of the grant date.
F6 On August 1, 2021, Ms. Olivo was granted 1,117 stock options. The options vest ratably over the first four anniversary dates of the grant date.
F7 On May 1, 2022, Ms. Olivo was granted 22,222 stock options. The options vest ratably over the first four anniversary dates of the grant date.
F8 On September 1, 2022, Ms. Olivo was granted 55,332 stock options. The options vest ratably over the first four anniversary dates of the grant date.
F9 On May 11, 2023, Ms. Olivo was granted 36,508 stock options. These options vest ratably over the first three anniversary dates of the grant date.
F10 On May 11, 2023, Ms. Olivo was granted 19,508 performance stock units representing the number of shares that may vest at target performance. The maximum number of shares that may vest pursuant to the performance criteria is29,262. The number of performance stock units that may vest is based on the achievement of certain share growth goals based on the weighted average price of the Company's common stock over the 20-day trailing trading period at theapplicable measurement dates, subject to continued service with the Company.
F11 On May 11, 2023, Ms. Olivo was granted 19,508 restricted stock units. These restricted stock units vest ratably over the first three anniversary dates of the grant date.
F12 On February 23, 2024, Ms. Olivo was granted 42,344 stock options. The options vest ratably over the first three anniversary dates of the grant date.
F13 On February 23, 2024, Ms. Olivo was granted 25,330 performance stock units representing the number of shares that may vest at target performance. The maximum number of shares that may vest pursuant to the performance criteria is37,996. 50% of the number of performance stock units that may vest is based on the achievement of certain share growth goals based on the weighted average price of the Company's common stock over the 20-day trailing trading period atthe applicable measurement dates, subject to continued service with the Company. 50% of the number of performance stock units that may vest is based on the achievement of certain revenue growth goals based on the achievement of thecumulative fiscal year revenue goal at the applicable measurement amounts, subject to continued service with the Company.
F14 On February 23, 2024, Ms. Olivo was granted 25,329 restricted stock units. These restricted stock units vest ratably over the first three anniversary dates of the grant date.